category,datetime,headline,id,image,related,source,summary,url
company,1768425641,Why Incyte (INCY) Stock Is Trading Up Today,138115689,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,INCY,Yahoo,"Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.2% in the afternoon session after TD Cowen maintained a 'Buy' rating on the stock and increased its price target. The firm's analyst, Marc Frahm, lifted the price target from $101.00 to $128.00, a significant increase of nearly 27%. This adjustment signaled a strong positive outlook for the company's future stock performance. The action from the analyst suggested a heightened confidence in the biopharmaceutical company",https://finnhub.io/api/news?id=351ef92c587b8c72ffa8dcb2d981a39d67a919f134bdf0f500a69ad8a29cadb5
company,1768410420,Incyte Corp. stock outperforms competitors on strong trading day,138138693,,INCY,MarketWatch,Incyte Corp. stock outperforms competitors on strong trading day,https://finnhub.io/api/news?id=c043d01d7e4e3da554d3eee97f7652a04485405f2994d216cc18d3f2651176da
company,1768388924,Is Incyte (INCY) Still Attractively Priced After Its Strong 1 Year Share Price Gain?,138110595,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,INCY,Yahoo,"If you are wondering whether Incyte's share price still offers value after its recent run, you are not alone. The stock closed at US$103.43 recently, with a 3% decline over the last 7 days, an 8.4% gain over 30 days, 2.0% year to date, 43.8% over 1 year and 10.1% over 5 years. This performance has many investors reassessing both opportunity and risk. Recent coverage has focused on how Incyte fits into the broader pharmaceuticals and biotech space, including ongoing interest in its product...",https://finnhub.io/api/news?id=2cd7f8f1b1a757c9ba77175388b442817e1814a18119562748369b5bd6aa249c
